Abstract 23
Introduction 24
Protease-activated receptors (PARs) evolved to react to extracellular proteolytic 25 activity. In mammals, three of the four PARs (PAR1, PAR3, and PAR4) that are 26 expressed respond to the prototypical procoagulant enzyme thrombin, whereas 27 PAR2 was assumed to resist activation by thrombin. To date, involvement of cell 28 surface thrombin-recruiting co-receptors such as thrombomodulin (TM), which 29 potentially facilitates PAR2 cleavage, has not been addressed. Thus, we examined 30 whether TM-bound thrombin cleaved PAR2 and tested biological responses such as 31 nuclear factor kappa B (NF-κB) DNA binding activity and cytokine release. 32 33
Materials and Methods 34
We examined 293T cells overexpressing PAR2 and TM for thrombin recruitment by 35 TM promoting PAR2 cleavage. To test for the TM-thrombin interactions required for 36 PAR2 cleavage and to map cleavage sites on PAR2, mutant constructs of TM or 37 PAR2 were engineered. Biological effects because of PAR2 activation were 38 investigated using an NF-κB reporter system and cytokine release. 39 40
Results and Conclusions 41
We identified that, at low to moderate concentrations, thrombin cleaved PAR2 in a 42 TM co-receptor-dependent manner with cleavage efficiency comparable to that of 43 trypsin. In TM's presence, thrombin efficiently cleaved both, PAR1 and PAR2, albeit 44 kinetics differed. Whereas the majority of surface expressed PAR1 was immediately 45 cleaved off, prolonged exposure to thrombin resulted in few additional cleavage. In 46 contrast, PAR2 cleavage was sustained upon prolonged exposure to thrombin. 47
However, TM EGF-like domain 5 was required and TM chondroitin sulfate (CS) 48 proteoglycan sites serine 490 and serine 492 assisted in PAR2 cleavage, while 49 thrombin preferentially cleaved at arginine 36 on PAR2's N-terminus. Note that 50 thrombin-induced activation of NF-κB via PAR2 resulted in release of interleukin-8. 51
Thus, we provide a novel concept of how thrombin efficiently cleaves PAR2 in a TM-52 dependent manner, resulting in pro-inflammatory interleukin-8 release. This 53 unexpected pro-inflammatory role of TM, promoting cleavage and activation of PAR2 54 Introduction 66
Clotting proteases elicit multiple physiological and pathophysiological responses 67 beyond clot formation. The family of PARs has evolved to allow cells to react to 68 presence of clotting (serine) proteases [1] . PARs belong to the seven-69 transmembrane G-protein-coupled receptor family. In mammals, the family of PARs 70 consists of four highly related serine protease receptors, i.e., . 71
Previously, PAR2 has been linked to inflammation-driven diseases of the brain, 72 cardiovascular system, lungs, joints, and gastrointestinal tract [8] [9] [10] [11] [12] [13] [14] [15] [16] , as well as 73 cancer growth [17, 18] , migration, and metastasis [9, 19] . Despite its importance in 74 pathophysiological processes, no treatments based on interference with PAR2 have 75 been established [20] . There are potential obstacles for defining therapeutic targets 76 because of the existence of multiple activation mechanisms and a large variety of 77 causal activating proteases [21] [22] [23] , as well as the complex nature of PAR2 78 compartmentalization and co-localization [19] . Recent studies that emphasize the 79 importance of PAR hetero-dimerization [24] , requirement of PAR2 co-localized co-80 receptors [22] , and introduction of the concept of biased PAR agonists [25] further 81 demonstrate the complexity of PAR2-related functions under physiological or 82 pathophysiological conditions. 83
To date, PAR2 has been assumed to resist activation by the prototypical 84 procoagulant protease thrombin, as it has not been observed to activate 85 overexpressed PAR2 in the absence of co-receptors [1, 5, 26] with anti-His#AD1.1.10 (2 µg/ml) and anti-TM_#501733 (1 µg/ml). Then, the plate 152 was washed and incubated with buffer or recombinant sTM (60 nM) to bind to anti-153 TM for 30 minutes. Synthetic PAR2 peptide (10 µg/ml) was bound to the plate by the 154 N-terminal His-tag (1 h). We added pre-warmed thrombin (30 nM) to the washed 155 plate and incubated the plate for 1 h at 37°C. The uncleaved (full length) PAR2 156 peptide was detected via the C-terminal biotin-tag using streptavidin-HRP and 157 quantified by a peroxidase-based enzyme immunoassay. LGC Standards GmbH, Wesel, Germany) were cultivated and propagated as 162 
Overexpression constructs 183
The overexpression constructs were embedded within the pcDNA3.1/Zeo(+) 184 (Thermo Fisher Scientific) expression plasmid, as described previously [34] . TM was 185 cloned from cDNA (obtained from RNA isolated from EA.hy926 endothelial cells) 186 using primers containing restriction sites (italics) HindIII and XhoI (forward: 5′-
GCTAAAGCTTGACAGGAGAGGCTGTCGCCATC-3′
and reverse: 5′-188 GCTACTCGAGGGGAATAAGTGGGGCTTGCT-3′). The HindIII/XhoI-digested PCR 189 product was directly introduced into the HindIII/XhoI-cut pcDNA3.1/Zeo(+) backbone. 190
For removal of N-terminal domains in TM, two unique BamHI restriction sites were 191 introduced by mutagenesis (NEB's plasmid mutation kit; Ipswich, MA, USA): the first 192 3′ from the signal sequence and the second 3′ from the sequence that encoded the 193 domain to be removed. Digestion of the mutated TM expression vector with BamHI 194 followed by plasmid re-ligation allowed dropping domains while maintaining the TM 195 native signal sequence (details are provided in Supplementary Table S1 ). Note that 196 TM chondroitin sulfate (CS) sites serine 490 and 492 were mutated to alanine with 197 the primer set (forward: 5′-CACGGCTCGACCTCAATG-3′, reverse: 5′-198 GGGGCTCGCCAGCGCCGGCGTCGCCACCGTCC-3′). 199 PAR1 and PAR2 alkaline phosphatase-tagged reporter ("AP-PAR1 and AP-200 PAR2") was as described elsewhere [34] . Sequence of the PAR4 alkaline 201 phosphatase-tagged reporter ("AP-PAR4") is described in Supplementary Table S4 . 202
In brief, an alkaline phosphatase (AP) tag (pSEAP; Clontech, CA, USA) was linked 203 to the N-terminus of PAR1 cDNA (F2R, NM_001992.4), PAR2 cDNA (F2RL1, 204 NM_005242.5), and PAR4 cDNA (F2RL3, NM_003950.3). Unlike the PAR2 205 construct mentioned elsewhere [34], an arginine (italics) at the C-terminal end of AP 206 (potential thrombin cleavage site) was removed using phosphorylated mutagenic 207 primers (forward: 5′-CCCGGGTTACTCTGCGGCCCAAGGAACCAATAG-3′; reverse: 208 5′-CTATTGGTTCCTTGGGCCGCAGAGTAACCCGGG-3′; Supplementary Table S2 ). 209
We inserted a green fluorescent C-terminal tag (EGFP; Clontech) analogous to a 210 procedure used in a previous study [34] (for details, see Supplementary Table S2  211 and Supplementary Scheme S1). To test for preferred cleavage sites on PAR2's N-212 terminal, arginine 36 was replaced by alanine ("PAR2 R36A;" protein sequence in 213 Supplementary  Table  S3 ) using mutagenic primers (forward: 214 5′-CCAATAGATCCTCTAAAGGAGCAAGCCTTATTGGTAAGG-3′; reverse: 215 5′-TTCCTTGGGCCGCAGAGTAACCCGGG-3′). Next, all potential thrombin 216 cleavage sites (arginine and lysine) were replaced by alanine ("PAR2 all-to-A" 217 mutant; protein sequence provided in Supplementary Table S3 ). Note that all 218 constructs that were used were verified by sequencing. 219 220
PAR cleavage reporter assay 221
The cleavage reporter assay was performed on 293T cells that transiently 222 expressing AP-PAR constructs ( Supplementary Table S2 ), as described elsewhere 223
[32]. In brief, washed cells were incubated with an agonist (for 20 minutes, or if 224 indicated, for repeated periods of 20 minutes), supernatants were removed and 225 filtered (cellulose ester filter; pore size, 0.45 µm), and AP activity was quantified Step PNPP; Thermo Fisher Scientific) by spectrophotometry (Labsystems Multiskan DNA and A549 cells that were silenced with siRNA 48 h prior to incubation with 236 agonists for 24 and 6 h, respectively. Then, IL-8 release was measured in 237 supernatants. As described previously, cell surface PAR2 and TM were quantified by 238 cell surface ELISA [50] . 239 240
Immunofluorescence microscopy 241
EGFP-tagged protein (Supplementary Scheme S1) was overexpressed using the 242 same protocols as that described for PAR cleavage reporter constructs and 243 visualized using appropriate filter sets of an Axiovert-10 fluorescent microscope (Carl 244
Zeiss AG, Feldbach, Switzerland). As described for the cell surface ELISA, untagged 245 proteins were incubated with antibodies; however, the secondary antibody carried an 246
Alexa-594 fluorescent tag (Thermo Fisher Scientific) rather than HRP. We analyzed and presented the data using GraphPad Prism5 (GraphPad Software, 261
La Jolla, CA, USA). To calculate the indicated P-values, a two-sample, two-tailed 262 homoscedastic t-test and one-way or two-way ANOVA with Bonferroni correction 263 were used. 264 265 266
Results

267
Effect of PAR2 activation by thrombin on IL-8 release in native A549 cells 268
Various studies showed expression of all PARs in lung epithelial cells promoting IL-8 269 release upon PAR agonist peptide stimulation due to PAR cis-or trans-activation 270
[51] [52] . In this study, we first tested the concentrations of PAR agonist peptides 271 required to induce IL-8 secretion in A549 cells. Similar to a previous study [53], we 272 found that A549 cells were induced to release IL-8 on incubation with the PAR2 273 agonist peptide SLIGRL, whereas the PAR1 agonist peptide TFLLRNPNDK and the 274 specific PAR4 agonist peptide AYPGKF demonstrated no such effect, even at high 275 concentrations. Unlike the PAR1-specific peptide, thrombin significantly induced IL-8 276 release from 30 to 100 nM ( Figure 1A ). To test whether thrombin induced IL-8 277 release could be linked to PAR2 activation, we relied on the PAR2-specific inhibitor 278 NDGA. NDGA did neither affect IL-8 release at baseline (buffer control) nor in highly 279
TNFα-induced A549 cells (not shown). However, NDGA significantly reduced IL-8 280 release by thrombin as well as by the PAR2-specific agonist SLIGRL ( Figure 1B) . 281
Consistently, silencing of PAR2 by siRNA abolished responses of A549 cells to 282 thrombin or SLIGRL induction ( Figure 1C ). In summary, IL-8 release by thrombin 283 stimulation was significantly reduced in PAR2-silenced or inhibited lung epithelial 284 cells, suggesting that thrombin plays a role in PAR2 signaling. 285 
Role of TM on PAR2 cleavage by thrombin 303
To test whether IL-8 induction by thrombin in epithelial cells of the lung could be 304 caused by direct cleavage of PAR2 using a co-receptor, we established a purified 305 system comprising immobilized PAR2 peptide with immobilized sTM and thrombin. 306 In this purified system, thrombin efficiently cleaved the PAR2 peptide in immobilized 307 sTM's presence; however, consistent with the established conclusion, thrombin 308 failed to directly cleave PAR2 in the co-receptor's absence (Figure 2A) . To test on 309 human cells whether physiologically achievable concentrations of thrombin cleaved 310 PAR2 and whether co-receptor(s) could be involved, we relied on the previously 311 established PAR cleavage reporter system [32, 34, 54] . To allow verification of 312 construct expression by assessing the tag's cell surface AP activity and monitor 313 cleavage by quantifying the activity of AP released into the supernatant, we 314 overexpressed PAR2 containing an AP enzyme domain at the N-terminus 315 ( Supplementary Table S2 ; Supplementary Scheme S1, [34]). PAR2 reporter and TM 316 constructs were expressed at the cell surface, which was further assessed by 317 fluorescence microscopy and cell surface ELISA. Co-expression of PAR2 and TM 318 did not affect expression of both constructs ( Supplementary Fig. S1a and S1b). In 319 such an overexpression system, free thrombin at concentrations up to 30 nM failed 320 to cleave PAR2 ( Figure 2B ), unlike the results of a recent study [27] . However, in 321 TM's presence, cleavage efficiency was significantly enhanced and, at low 322 nanomolar concentrations of proteases, thrombin and trypsin showed comparable 323 cleavage efficiency ( Figure 2C ). To test whether thrombin/TM could mediate release 324 or activation of another protease, which ultimately cleaved PAR2, we added 325 thrombin-induced supernatant from TM-expressing cells to 1) PAR2-and 2) PAR2-326 and TM-expressing cells, for assessing PAR2 cleavage. We identified that, in the 327 absence of TM, PAR2 was not cleaved and, wherever thrombin in supernatant was 328 blocked by the specific inhibitor lepirudin, cleavage was blunted ( Figure 2D ). Addition 329 of activated protein C or inhibition of metalloproteases did not affect PAR2 cleavage 330 by thrombin ( Supplementary Fig. S3a and S3b) . Therefore, overall, these results 331 cannot support a model whereby thrombin induces a PAR2-cleaving protease. To 332 simulate more physiological conditions where PAR1, PAR2 and TM are co-333 expressed, and to test whether the co-expression impacts cleavage, we 334 overexpressed 1) PAR1 containing an N-terminal AP enzyme tag together with 335 untagged-PAR2 or 2) PAR2 containing an N-terminal AP enzyme tag together with 336 an untagged-PAR1 ( Supplementary Table S2 ; Supplementary Scheme S1, [34]) in 337 presence or absence of TM. As expected, PAR1 was rapidly cleaved by thrombin (5 338 and 30 nM) while PAR2 -in TM's presence -was more efficiently cleaved upon 339 prolonged thrombin exposure (5 and 30 nM) ( Figure 2E and 2F) . The cleavage of 340 PAR2 at 60 minutes of exposure to thrombin (30 nM) was comparably efficient to the 341 PAR1 cleavage at 20 minutes ( Figure 2F ). Cleavage of PAR2 was sustained upon 342 prolonged exposure to thrombin for up to 25 hours ( Supplementary Fig. S4a-c ). Note 343 that, upon a exposure to thrombin for 3 hours, a broad range of thrombin 344 concentrations from 1 to 30 nM resulted in significant cleavage of PAR2 345 ( Supplementary Fig. S4a-c) . Our observations suggest that TM-bound thrombin 346 directly cleaves PAR2 in our overexpression system and that TM dependent 
Importance of interactions between TM EGF-like domains and CS with 382 thrombin exosite I and exosite II on PAR2 cleavage 383
Next, we addressed domains of TM required for increasing PAR2 cleavage by 384 thrombin. TM contains six epidermal growth factor (EGF)-like domains, from which 385 EGF-like domain 4 was linked to protein C substrate acceptance, whereas EGF-like 386 domains 5 and 6 were linked to thrombin recruitment [55] to the cell surface. To test 387 whether these EGF-like domains were involved in promoting PAR2 cleavage, we 388 produced N-terminally truncated mutants of TM ( Supplementary Table S1 ). The 389 mutants were expressed and recognized as expected by cell surface ELISA using 390 anti-TM targeting EGF-like domains 5 and 6 ( Supplementary Fig. S5 ). Note that 391 PAR2 was efficiently cleaved when wild-type TM or mutants containing EGF-like 392 domains 5 and 6 were present. The TM mutant composed of only EGF-like domain 6 393 failed to promote the cleavage of PAR2 by thrombin ( Figure 3A) . 394
Moreover, interactions between thrombin exosite II and CS on TM were involved 395
for thrombin recruitment [56] and to enhance the endothelial protein C pathway. To 396 test whether such interactions between exosite II and CS facilitated PAR2 cleavage 397 by thrombin, we synthesized a TM mutant that lacked the serine 490 and 492 glycosylation sites. Similar to the conclusions from the protein C pathway that 399 interactions between exosite II and CS assist with thrombin recruitment toward TM, 400 CS-deficient mutant of TM was less efficient for supporting the cleavage of PAR2 by 401 thrombin (Figure 3B) . Similarly, blocking the interactions of exosite II with CS with an 402 aptamer, a short single-stranded DNA specifically blocking exosite II [49], interfered 403 with PAR2 cleavage ( Figure 3C ). Supporting this observation, PAR2 cleavage was 404 reduced by exosite II binding agent heparin ( Supplementary Fig. S2 ). Unlike exosite 405 II and TM interaction, the interaction of exosite I with EGF-like domain 5 and 6 of TM 406 is considered essential for thrombin recruitment [57] . Moreover, blocking exosite I by 407
an aptamer [48] blunted PAR2 cleavage by thrombin ( Figure 3C) . 408
To test whether sTM supports PAR2 cleavage by thrombin, thrombin was pre-409 incubated with recombinant sTM that lacks the membrane anchor. The mixture was 410 then tested for PAR2 cleavage. In the absence of cell surface-expressed TM, sTM-411 thrombin mixture failed to significantly cleave PAR2 ( Figure 3D ). This observation 412 supports either the lack of sTM's role in assisting PAR2 cleavage by thrombin or the 413 failure of our cells to recruit sTM-thrombin complexes onto the cell surface. 414
Thus, similar to our observations of the protein C pathway, our data suggest that, 415 pre-incubation at 37°C for complex formation). Data are presented as mean ± SEM; 438
three independent experiments were each performed in triplicate; ns p > 0.05, * p < 439 0.05, ** p < 0.01, *** p < 0.001, using student's t test. 440 441
Role of PAR2 N-terminal arginine 36 in cleavage by thrombin 442
Previous evidence suggested that PARs harbor a unique cleavage site that 443 promotes initiation of biological effects [1] . Recently, however, studies have revealed 444 that PARs behave as "multi-switches" with several cleavage sites, resulting in 445 cleavage-site-specific biological effects [23, 34, 35, 58] and referred to as biased 446 signaling. Thus, we investigated whether TM-bound thrombin cleaved PAR2 at 447 specific sites. Similar to our studies in PAR1 and PAR3 [34], we synthesized mutants 448 of PAR2 with alanine (A) substitutions for the positively charged amino acids arginine 449 (R) and lysine (K) in the extracellular N-terminal domain ( Supplementary Table S3 ). 450
A mutant of PAR2 that was devoid of all R and K on the entire N-terminal domain 451
("PAR2 all-to-A" mutant; Supplementary Table S3 ) resisted cleavage by thrombin 452 ( Figure 4A ). Removal of canonical R36 ("PAR2 R36A" mutant; Supplementary Table  453 S3) yielded an almost thrombin-resistant mutant ( Figure 4B) ; however, additional 454 sites at which cleavage occurs inefficiently might be present. Thus, our data suggest 455 that R36 is the preferred cleavage site of TM-bound thrombin; however, the 456 existence of additional cleavage site(s) cannot be ruled out. constructs. The mutant "AP-PAR2 all-to-A" contained no positively charged amino 463 acids in the N-terminal PAR2 domain and in the "AP-PAR2 R36A" mutant, arginine 464 36, was replaced by alanine (details provided in Supplementary Table S3 ). Cells 465
were incubated with thrombin (30 nM) for 20 minutes before PAR2 cleavage was 466 measured. Data are presented as mean ± SEM; three independent experiments 467 were each performed in triplicate; (A-B) ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 468 0.001, using student's t test. 469 470
Role of the NF-κB pathway downstream of thrombin-cleaved PAR2 471
Previously, pro-inflammatory signaling was reported to occur because of PAR2 472 activation by other proteases that cleaved PAR2 at R36 [11] [12] [13] . Thus, we 473 investigated whether TM-bound thrombin cleaved PAR2 and induced pro-474 inflammatory signaling via NF-κB activation. In our commercial NF-κB reporter 475 system, thrombin failed to induce NF-κB activation when PAR2 and TM were absent 476 or expressed alone ( Supplementary Fig. S6a ). NF-κB DNA binding activity, however, 477 increased in a manner dependent on thrombin concentration due to the availability of 478 PAR2 and TM ( Figure 5A ). PAR2 agonist peptide SLIGRL induced NF-κB DNA 479 binding activity in PAR2 and TM overexpressing cells similarly to thrombin; however, 480 >1000 times higher concentrations of agonist peptide was required to obtain 481 comparable induction ( Figure 5A ). Similar to thrombin, the PAR1 agonist peptide 482 TFLLRNPNDK induced NF-κB activation only if PAR1 was overexpressed. Similarly, 483 the PAR4 agonist peptide AYPGKF induced NF-κB activation only in cells 484 overexpressing PAR4. As expected, the PAR4 activation by thrombin was less 485 efficient compared to PAR1 activation. In the absence of overexpressed PAR1 or 486 PAR4, agonist peptides showed no such effect, similar to TFLLRNPNDK and 487 AYPGKF failing to activate endogenous PAR1 or PAR4 in these cells and consistent 488 with TFLLRNPNDK and AYPGKF failing to activate overexpressed PAR2 in this 489 system. However, similar to the PAR2 agonist peptide SLIGRL, thrombin-induced 490 NF-κB activation via PAR2 only in the presence of TM ( Supplementary Fig. S6b ). 491
Moreover, consistent with our conclusions from the PAR2 cleavage reporter 492 assay, EGF-like domain 5 of TM was required for thrombin-and PAR2-mediated 493 induction of NF-κB activation ( Figure 5B ). 494
We then tested whether thrombin's preferred cleavage site R36 was important 495 for NF-κB induction. In R36's absence, our assays showed diminished cleavage of 496 PAR2 and no induction of NF-κB activation ( Figure 5C ). 497
We then addressed the signal pathways downstream of PAR2 but upstream of 498 NF-κB activation. Phosphatidylinositol 3-kinase (PI3K) pathway is an important 499 regulator of NF-κB activation and potentially links PAR2 cleavage and activation to 500 the NF-κB pathway. To test whether the induction of NF-κB activation after PAR2 501 cleavage occurred via PI3K, we used the PI3K inhibitor LY294002. Consistent with 502 PI3K linking PAR2 and NF-κB, LY294002 interfered with NF-κB activation by 503 thrombin and activation by PAR2-specific peptide SLIGRL ( Figure 5D ). 504
Note that 293T cells secreted IL-8 with the overexpression of PAR2 and SLIGRL 505 agonist induction. However, as shown previously [34] and in Supplementary Fig. S6b , 506 cells remained quiescent upon incubation with the PAR1 agonist peptide, which 507 confirms our previous conclusion that, without transfection, these cells would not 508 respond to PAR agonists. Note that thrombin-stimulated 293T cells overexpressing 509 PAR2 alone remained quiescent. However, in cells expressing TM and PAR2, 510 thrombin (30 nM) and SLIGRL (50 µM) were comparably efficient for inducing the 511 release of IL-8 ( Figure 5E ). Thus, our data suggest that PAR2 cleaved at R36 by 512 TM-bound thrombin induced NF-κB DNA binding activity via PI3K and ultimately 513 released IL-8 release ( Figure 5F ). Thus, we suggest that PAR1 is responsible for rapid thrombin responses while PAR2 554 sustains the thrombin signaling following PAR1 desensitization. In fact, PAR2 555 cleavage by thrombin was most efficient at the canonical cleavage site arginine 36. 556
Note that this study establishes a direct link of cleavage of PAR2 by thrombin to pro-557 inflammatory signaling such as activation of NF-κB pathway and release of IL-8 in 558 natively PAR2-and TM-expressing A549 lung epithelial cells. To date, PAR2 has 559 been assumed to be distinct in the family of PARs in terms of resisting cleavage and 560 activation by thrombin [1, 5, 26] . However, biological effects of thrombin have now 561 been linked to PAR2, although the exact mechanism of activation needs to be 562 clarified. [22] , 577 or platelet-expressed PAR4 by thrombin [62], we postulated that, for efficient PAR2 578 activation by thrombin, a co-receptor was required. Indeed, we discovered a novel 579 co-receptor function of TM, supporting the cleavage and activation of PAR2 by 580 thrombin. Indeed, TM's presence increased thrombin's efficiency for cleaving PAR2. 581
Other potential PAR2 cleaving proteases induced or activated by thrombin or the 582 thrombin-TM complex were ruled out. Highlighting the plausibility of the presence of 583 TM playing a physiological role, 5 nM thrombin and 5 nM trypsin cleaved PAR2 with 584 comparable efficiency. Because TM is not the only cell surface receptor for thrombin 585
[64], other surface recruiting receptors might contribute to further PAR2 activation by 586 thrombin and explain the PAR2-dependent effects of thrombin in cells that did not 587 express TM.
We identified that the EGF-like domain 5 of TM and exosite I in 588 thrombin were important for TM-promoted PAR2 cleavage and NF-κB pathway 589 activation by thrombin. Furthermore, this conclusion was supported by removing the 590 EGF-like domains on TM and by blocking thrombin exosite I site using a small 591 specific aptamer. Our observations reinforce previous research on TM [55] , showing 592 that in the context of the protein C pathway the described interaction is required for 593 cell surface recruitment of thrombin. Similarly, interactions between exosite II and CS 594 help in thrombin recruitment [57] . Furthermore, we found that exosite II blocking 595 aptamers or exosite II binding heparin interfere with PAR2 cleavage by thrombin. 596
These results are in accordance with a recently published study that links the TM 597 glycosaminoglycan domain to immune responses [65] . 598
Thus, our data confirms that thrombin activates NF-κB and induces IL-8 release 599
for overexpressing 293T cells and triggers IL-8 release in A549 cells in a TM-and 600 PAR2-dependent manner. The specific PAR2 agonist SLIGRL induced IL-8 release, 601 supporting PAR2 stimulation to be sufficient for IL-8 release. Complementary, 602
interfering with PAR2 either via inhibition (NDGA) or knock down (siRNA) 603 significantly reduced responsiveness to thrombin and SLIGRL of natively PAR2 604 expressing A549 cells. Although thrombin-induced IL-8 release was significantly 605 reduced in PAR2 silenced or inhibited cells, we failed to render our system fully 606 thrombin irresponsive. Possible explanations include incomplete PAR2 knock down, 607 or another (yet to be identified) thrombin receptor induced IL-8 release. 608
With such a well-characterized system, we provided evidence that co-receptor-609 bound thrombin directly activates pro-inflammatory pathways via PAR2. Our 610 evidence confirms that A549 cells did not release IL-8 on stimulation with PAR1 611 agonist peptide. This result is consistent with that of a recent study [53] . Our results 612 support that prolonged thrombin signaling via PAR2 / TM could explain pro-613 inflammatory signaling in A549 alveolar cells. In view of thrombin inhibition 614 ameliorating chronic inflammation of the lung as reviewed in [66] one is tempted to 615 speculate, that thrombin / TM / PAR2 might serve as underlying mechanism. Thus, 616 stimulation of PAR2 by extravascular thrombin might contribute to inflammatory 617 diseases of the lung. 618
Our conclusion that thrombin activates PAR2 via the co-receptor TM is heavily 619 reliant on overexpression systems; thus, the physiological relevance of this has yet 620 to be established completely. The confirmation of our concept in a single cell line, i.e., 621 A549 natively expressing PAR2 and TM, cannot eliminate this important limitation. 622
However, to summarize, we provide the first evidence that TM-bound thrombin 623 cleaves and activates PAR2 efficiently at low to moderate nanomolar concentrations 624 and that this pathway of NF-κB activation results in the release of IL-8 in PAR2-and TM-overexpressing and natively expressing cells. Further studies will be required to 626 link this novel signaling pathway to important pathophysiological processes, 627 particularly for chronic inflammatory diseases such as asthma, arthritis, and cancer. 628
Note that such studies may reveal novel therapeutic strategies for diseases that are 629 linked to PAR2. 630 631 632
